Ken Griffin Acelrx Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.2 - $0.35 $21,783 - $38,120
108,916 New
108,916 $23,000
Q2 2022

Aug 15, 2022
SELL
$0.18 - $0.29 $16,642 - $26,813
-92,459 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$0.28 - $0.61 $43,264 - $94,255
-154,517 Reduced 62.56%
92,459 $27,000
Q4 2021

Feb 14, 2022
BUY
$0.49 - $1.02 $108,469 - $225,794
221,367 Added 864.41%
246,976 $138,000
Q3 2021

Nov 15, 2021
SELL
$0.93 - $1.51 $10,756 - $17,464
-11,566 Reduced 31.11%
25,609 $26,000
Q2 2021

Aug 16, 2021
SELL
$1.03 - $1.7 $29,808 - $49,198
-28,940 Reduced 43.77%
37,175 $51,000
Q1 2021

May 17, 2021
SELL
$1.25 - $2.77 $14,720 - $32,619
-11,776 Reduced 15.12%
66,115 $112,000
Q4 2020

Feb 16, 2021
BUY
$1.18 - $1.98 $70,356 - $118,055
59,624 Added 326.4%
77,891 $97,000
Q3 2020

Nov 16, 2020
BUY
$1.01 - $1.81 $1,722 - $3,086
1,705 Added 10.29%
18,267 $26,000
Q2 2020

Aug 14, 2020
SELL
$1.03 - $1.69 $84,684 - $138,948
-82,218 Reduced 83.23%
16,562 $20,000
Q1 2020

May 15, 2020
BUY
$0.76 - $2.07 $54,027 - $147,154
71,089 Added 256.72%
98,780 $117,000
Q4 2019

Feb 14, 2020
SELL
$1.66 - $2.4 $51,486 - $74,438
-31,016 Reduced 52.83%
27,691 $58,000
Q3 2019

Nov 14, 2019
SELL
$2.1 - $2.87 $45,164 - $61,725
-21,507 Reduced 26.81%
58,707 $129,000
Q2 2019

Aug 14, 2019
SELL
$2.1 - $3.93 $50,173 - $93,895
-23,892 Reduced 22.95%
80,214 $203,000
Q1 2019

May 15, 2019
SELL
$2.35 - $3.83 $12,821 - $20,896
-5,456 Reduced 4.98%
104,106 $0
Q3 2018

Nov 13, 2018
SELL
$2.6 - $4.6 $25,482 - $45,084
-9,801 Reduced 8.21%
109,562 $0
Q2 2018

Aug 10, 2018
BUY
$2.13 - $4.2 $96,974 - $191,217
45,528 Added 61.66%
119,363 $0
Q1 2018

May 11, 2018
SELL
$1.7 - $2.35 $138,249 - $191,109
-81,323 Reduced 52.41%
73,835 $155,000
Q4 2017

Feb 09, 2018
BUY
$1.75 - $5.5 $83,734 - $263,164
47,848 Added 44.59%
155,158 $314,000
Q3 2017

Nov 09, 2017
BUY
$2.9 - $4.6 $311,199 - $493,625
107,310
107,310 $494,000

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email